)
)
)
Autoimmunity BioSolutions
- Genetically driven, personalized immuno-corrective therapy in autoimmune disease.
- Addressing the significant unmet need in many autoimmune diseases - 50% non-response to current standards of care
- Initial indications RA, Lupus, T1D
- Founders identified a genetic risk population - 50% of the population with genetically unregulated sIL7R that corresponds with poor response to therapy
- Innovative approach to defining and de-risking initial POC studies with patient bio-sample studies
- Experienced management team
- Seeking $2MM-$4MM seed extension round in 2026
Address
HoustonTexas
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)